clinical trial · NCT06832410
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
Vertex Pharmaceuticals Incorporated·phase3·recruiting·n = 10
Type 1 DiabetesKidney TransplantBiological/Vaccine
brief summary
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
started
Mar 31, 2025
primary completion
Sep 17, 2026
completion
Sep 17, 2027
last updated
Mar 23, 2026
official title
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol